The use of emoxipin for correction of cyclophosphamide cytotoxicity in experimental animals.
In experiments on animals with Lewis lung carcinoma, emoxipin decreased hematotoxicity of cyclophosphamide without reducing its antitumor efficiency (effect on primary tumor node). Combined administration of emoxipin and cyclophosphamide more effectively prevented the development of metastases compared to cytostatic monotherapy.
Siprov
A V
AV
N. P. Ogarev Mordovian State University, Saransk, Russia. alek-s13@mail.ru
Kinzirskaya
Yu A
YA
D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects* / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use*; D001854:Bone Marrow Cells / Q000187:drug effects; D003520:Cyclophosphamide / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D051379:Mice; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000188:drug therapy*; D010847:Picolines / Q000627:therapeutic use*
D018906:Antineoplastic Agents, Alkylating; D000975:Antioxidants; D010847:Picolines; D003520:Cyclophosphamide; C009820:6-methyl-2-ethyl-3-hydroxypyridine